Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab with Chemotherapy for Poor Prognosis AML
NCT05697510Phase 1Unknown
- Sponsor
- CHU de Nantes
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siltuximab in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Primary endpoint: Dose Limiting Toxicity at 45 days. Status: unknown.
02
Drugs
siltuximab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05697510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697510.